

CC0651

Catalog No: tcsc2109



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

1319207-44-7

Formula:

$C_{20}H_{21}Cl_2NO_6$

Pathway:

Metabolic Enzyme/Protease

Target:

E1/E2/E3 Enzyme

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 56 mg/mL (126.61 mM)

Observed Molecular Weight:


442.29

Product Description

CC0651 is an allosteric inhibitor of the human **Cdc34 ubiquitin-conjugating enzyme**. CC0651 potently (**IC₅₀**=1.72 μ M) inhibits the ubiquitination of p27^{Kip1}, as confirmed by dose-response analysis.

IC50 & Target: IC50: 1.72 μ M (p27^{Kip1} ubiquitination)^[1]

In Vitro: CC0651 strongly impairs the rate of ubiquitin chain initiation on substrate by SCF^{Cdc4}, as measured by the monoubiquitination of Sic1 by K0 ubiquitin. CC0651 actually potentiates the formation of both ubiquitin dimers and monoubiquitinated hCdc34, concordant with the observed accumulation of the hCdc34 conjugate in cells treated with the ester derivative of CC0651. CC0651 completely inhibits the assembly of polyubiquitin chains and decreased formation of free triubiquitin and, to a lesser extent, hCdc34 monoubiquitin, but has no effect on production of diubiquitin^[1]. CC0651 is an inhibitor of the E2 ubiquitin conjugating enzyme Cdc34A, acts by trapping a weak interaction between ubiquitin and the E2 donor ubiquitin binding site. A quantitative SCF ubiquitination assay with a β -Catenin substrate peptide yields a value of IC₅₀ of 18 \pm 1 μ M for CC0651 inhibition, similar to the effective concentrations observed in the NMR and TR-FRET assays^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!